Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells $474,045.00 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Carlo Incerti sold 16,500 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $29.99 on Thursday. The company has a market cap of $3.05 billion, a P/E ratio of -8.42 and a beta of 1.10. Dyne Therapeutics, Inc. has a 12 month low of $10.03 and a 12 month high of $47.45. The company has a 50-day moving average of $32.31 and a 200-day moving average of $35.25.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.25). As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.39 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have issued reports on DYN. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Guggenheim raised their target price on Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Piper Sandler reiterated an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Finally, JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Nisa Investment Advisors LLC raised its holdings in Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares during the period. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd acquired a new position in shares of Dyne Therapeutics during the third quarter worth about $36,000. US Bancorp DE boosted its position in shares of Dyne Therapeutics by 776.9% in the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after buying an additional 1,212 shares during the period. Finally, Values First Advisors Inc. acquired a new stake in shares of Dyne Therapeutics in the third quarter valued at about $62,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.